Day: September 12, 2021

<div>Dolby and Justin Bieber Team Up to Go Inside the Story of his Latest Single "Ghost"</div>

Dolby and Justin Bieber Team Up to Go Inside the Story of his Latest Single “Ghost”

Fans can enjoy “Ghost” and his latest multi-platinum album JUSTICE today in Dolby Atmos on Apple Music Dolby Atmos X Justin Bieber Fans can enjoy “Ghost” and Justin Bieber’s latest multi-platinum album JUSTICE today in Dolby Atmos on Apple Music Dolby teamed up with global superstar Justin Bieber to celebrate his latest single “Ghost” and a new era for music in Dolby Atmos. SAN FRANCISCO, Sept. 12, 2021 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, teamed up with global superstar Justin Bieber to celebrate his latest single “Ghost” and a new era for music in Dolby Atmos, which is transforming how music is created and enjoyed. In this long-form commercial, the world will see the versatility of Justin’s musical talent while exploring...

Continue reading

Dolby Teams up with The Weeknd to Explore How He Creates Worlds with Music

Dolby Teams up with The Weeknd to Explore How He Creates Worlds with Music

Fans can enjoy The Weeknd’s Latest Single “Take My Breath” in Dolby Atmos on Apple Music The Weeknd X Dolby Atmos Fans can enjoy The Weeknd’s Latest Single “Take My Breath” in Dolby Atmos on Apple Music. Dolby teamed up with The Weeknd to celebrate a new era for music in Dolby Atmos, which is transforming how music is created and enjoyed. SAN FRANCISCO, Sept. 12, 2021 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, teamed up with The Weeknd to celebrate a new era for music in Dolby Atmos, which is transforming how music is created and enjoyed. The long-form commercial explores how The Weeknd creates sensory experiences through music. Fans looking to connect with The Weeknd on a deeper, more emotional level, can experience his recently released...

Continue reading

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology (ESMO) Virtual Conference, taking place September 16-21, 2021. Posters will be available on September 16, 2021. Details are as follows: 620P – MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion Preliminary clinical results from the Phase 1 cohort expansion study of MGC018 in patients with metastatic castration-resistant prostate cancer and non-small cell lung cancer will...

Continue reading

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Bologna-based RADIUS S.r.l. (Radius) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market. This agreement builds on the support Radius has provided Telix in distributing 68Ga-PSMA-11 for magisterial use in Italy. Under the terms of the agreement, Radius will be the exclusive commercial distributor of Illuccix® in Italy, an EU5 country, for a period of three years from the national approval date. Radius is the market leader in the supply of gallium generators across Italy, a position which enables Radius to provide...

Continue reading

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing Phase 1b/2 trial of BXCL701, the Company’s investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology (ESMO) Congress, which will take place virtually from September 16-21, 2021. POSTER PRESENTATION DETAILS Title: BXCL701—1st-in-class oral activator of systemic innate immunity—combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results Poster...

Continue reading

Victoria Gold – Record Setting Gold Production and Corporate Update

Victoria Gold – Record Setting Gold Production and Corporate Update

Eagle Gold Mine Produces over 20,000 ozs in August WHITEHORSE, Yukon, Sept. 12, 2021 (GLOBE NEWSWIRE) — Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is pleased to have achieved record gold production at the Eagle Gold Mine, Yukon Territory and to provide a Corporate Update ahead of the Denver Gold Forum. “The Eagle Gold Mine produced a record 20,744 ounces gold in August with more than 1 million tonnes of ore stacked on the heap leach pad in each of July and August, setting the stage for strong Q3 operational performance,” stated John McConnell, President & CEO. “Additionally, exploration remains in full swing and we look forward to providing results in the near future.” Eagle Gold Mine July & August 2021 Production Results     July August YTD Operating Data         Ore mined 000’s of tonnes 1,263 892 6,004 Waste...

Continue reading

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Figure 1 Change from Baseline in NT-proBNP and NYHA Class Figure 2 Primary Outcome in Black Patients Enrolled in GALACTIC-HF Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Treatment with Omecamtiv Mecarbil in Black Patients Consistent with Overall Population and White Patients Cytokinetics to Host Investor/Media Event and Webcast on September 13, 2021 at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 12, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274...

Continue reading

MISTRAS Group to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

MISTRAS Group to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

PRINCETON JUNCTION, N.J., Sept. 12, 2021 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE) – a leading “one source” global provider of technology-enabled asset protection solutions used to maximize the uptime and safety of critical energy, industrial, and public infrastructure – announced today that Dennis Bertolotti, Chief Executive Officer, and Edward Prajzner, Chief Financial Officer, will be presenting at the H.C. Wainwright Global Investment Conference, which is being held virtually from September 13-15, 2021. Management will also be hosting virtual one-on-one meetings throughout the conference. Investors may listen to the presentation online beginning on September 13 at 7:00 A.M. (ET) via the link below: https://journey.ct.events/view/84210c38-b989-483f-b315-59af40408a21. About MISTRAS Group, Inc. – One Source for Asset...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.